The inhibition of PD-1 engagement by the use of pembrolizumab increases the number of CD8+ T cells during liver metastasis resulting from melanoma and the NSCLC while the number of CD8+ T cells at the invasive margin is declined dramatically [69]. Here, CD8A is linked to melanoma.